{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:11:03Z","timestamp":1790683863742,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,4]]},"DOI":"10.7759\/cureus.75079","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T10:39:26Z","timestamp":1733308766000},"source":"Crossref","is-referenced-by-count":1,"title":["Concurrent Onset of Osimertinib-Induced Heart Failure and Metronidazole-Induced Encephalopathy During Brain Abscess Treatment: A Report of a Rare Case"],"prefix":"10.7759","author":[{"given":"Emi","family":"Mikami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shiono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.02.003","article-title":"Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib","volume":"2","author":"Kunimasa K","year":"2020","unstructured":"Kunimasa K, Kamada R, Oka T, et al.. Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib. JACC CardioOncol. 2020, 2:1-10. 10.1016\/j.jaccao.2020.02.003","journal-title":"JACC CardioOncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01171","article-title":"Cardiac safety of osimertinib: a review of data","volume":"39","author":"Ewer MS","year":"2021","unstructured":"Ewer MS, Tekumalla SH, Walding A, Atuah KN. Cardiac safety of osimertinib: a review of data. J Clin Oncol. 2021, 39:328-37. 10.1200\/JCO.20.01171","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15736","article-title":"Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight","volume":"114","author":"Fujiwara Y","year":"2023","unstructured":"Fujiwara Y, Makihara R, Hase T, et al.. Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight. Cancer Sci. 2023, 114:2087-97. 10.1111\/cas.15736","journal-title":"Cancer Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9147-6","article-title":"Metronidazole-induced encephalopathy: a systematic review","volume":"267","author":"S\u00f8rensen CG","year":"2020","unstructured":"S\u00f8rensen CG, Karlsson WK, Amin FM, Lindelof M. Metronidazole-induced encephalopathy: a systematic review. J Neurol. 2020, 267:1-13. 10.1007\/s00415-018-9147-6","journal-title":"J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-023-08566-w","article-title":"Frequency and risk factor analysis for metronidazole-associated neurologic adverse events","volume":"39","author":"Lee SJ","year":"2024","unstructured":"Lee SJ, Kim J, Lee KH, et al.. Frequency and risk factor analysis for metronidazole-associated neurologic adverse events. J Gen Intern Med. 2024, 39:912-20. 10.1007\/s11606-023-08566-w","journal-title":"J Gen Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of obesity on drug metabolism and elimination in adults and children","volume":"51","author":"Brill MJ","year":"2012","unstructured":"Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012, 51:277-304. 10.2165\/11599410-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-012-0029-2","article-title":"Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously)","volume":"52","author":"Ogawa R","year":"2013","unstructured":"Ogawa R, Stachnik JM, Echizen H. Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously). Clin Pharmacokinet. 2013, 52:169-85. 10.1007\/s40262-012-0029-2","journal-title":"Clin Pharmacokinet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198308010-00003","article-title":"Clinical pharmacokinetics of metronidazole","volume":"8","author":"Ralph ED","year":"1983","unstructured":"Ralph ED. Clinical pharmacokinetics of metronidazole. Clin Pharmacokinet. 1983, 8:43-62. 10.2165\/00003088-198308010-00003","journal-title":"Clin Pharmacokinet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199223050-00002","article-title":"Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives","volume":"23","author":"Lau AH","year":"1992","unstructured":"Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet. 1992, 23:328-64. 10.2165\/00003088-199223050-00002","journal-title":"Clin Pharmacokinet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/320929-concurrent-onset-of-osimertinib-induced-heart-failure-and-metronidazole-induced-encephalopathy-during-brain-abscess-treatment-a-report-of-a-rare-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T10:39:27Z","timestamp":1733308767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/320929-concurrent-onset-of-osimertinib-induced-heart-failure-and-metronidazole-induced-encephalopathy-during-brain-abscess-treatment-a-report-of-a-rare-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.75079","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,4]]}}}